您当前的位置：

Sodium salicylate

(Synonyms: 水杨酸钠; Salicylic acid sodium salt; 2-Hydroxybenzoic acid sodium salt)

目录号: PC11557 纯度: ≥98%

NF-κB 抑制剂,Sodium Salicylate 抑制 COX-2 活性，抑制作用与转录因子 (NF-κB) 激活无关。

CAS No. :54-21-7

商品编号	规格	价格	会员价
PC11557-10g	10g	¥471.00	请登录
PC11557-50g	50g	¥726.00	请登录
PC11557-10mM (in 1mL DMSO)	10mM (in 1mL DMSO)	¥637.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Sodium salicylate
中文别名	水杨酸钠;邻羟基苯甲酸钠;2-羟基苯甲酸单钠盐;柳酸钠;杨酸钠;2-羟基苯甲酸钠;水扬酸钠;水楊酸鈉;食品级水杨酸钠;水杨酸钠 EP标准品;水杨酸钠 USP标准品;水杨酸钠分析纯化学试剂;水杨酸钠,AR;水杨酸钠,CP;水杨酸钠AR(沪试);医药级水杨酸钠;柳酸钠,2-羟基苯甲酸单钠盐,邻羟基苯甲酸钠,杨酸钠;水杨酸;水杨酸钠 ;2-羟基苯甲酸钠盐;水杨酸钠盐;水杨酸钠，医药级,纯度:>99%
英文名称	Sodium salicylate
英文别名	Sodium salicylate;sodium salicylate usp;Salicylic acid sodium salt;salicylic acid sodium;Sodium sallicylate;Salicylic acid, sodium saltSodium;o-hydroxybenzoic sodium salt;Sodium 2-Hydroxybenz;Sodium 2-Hydroxybenzoate;2-Hydroxybenzoic acid sodium salt;alysine;ardall;aroall;clin;diuretin;kerosal;magsalyl;nadisal;NASAL;Salicylic acid;salicylic acid monosodium salt;salisod;SodiuM o-hydroxybenzoate;水杨酸钠;Salsonin;Enterosalicyl;Glutosalyl;Kerasalicyl;Entrosalyl;Enterosalil;Idocyl novum;Neo-salicyl;Parbocyl-rev;Benzoic acid, 2-hydroxy-, monosodium salt;Monosodium salicylate;Sodium o-hydroxybenzoate;Natrium salicylat [German];Salicylic acid, sodium salt;Monosodium 2-hydroxybenzoate;Salicylic acid Na+;Salicylic Acid, Na;o-Hydroxy; 2-Hydroxybenzoic acid sodium salt
Cas No.	54-21-7
分子式	C₇H₅NaO₃
分子量	160.10
包装储存	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

生物活性

Sodium Salicylate (Salicylic acid sodium salt) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation. Sodium Salicylate is also a S6K inhibitor.Sodium Salicylate is a NF-κB inhibitor that decreases inflammatory gene expression and improves repair in aged muscle.

性状

Solid

IC50 & Target[1][2]

COX-2

Microbial Metabolite

Autophagy

S6K

体外研究(In Vitro)

Sodium Salicylate is an effective inhibitor of COX-2 activity at concentrations far below those required to inhibit NF-κB (20 mg/mL) activation. Sodium Salicylate inhibits prostaglandin E₂ release when add together with interleukin 1β for 24 hr with an IC₅₀ value of 5 μg/mL, an effect that is independent of NF-κB activation or COX-2 transcription or translation. Sodium Salicylate acutely (30 min) also causes a concentration-dependent inhibition of COX-2 activity measured in the presence of 0, 1, or 10 μM exogenous arachidonic acid. In contrast, when exogenous arachidonic acid is increased to 30 μM, Sodium Salicylate is a very weak inhibitor of COX-2 activity with an IC₅₀ of >100 μg/mL. When added together with IL-1β for 24 hr, Sodium Salicylate causes a concentration-dependent inhibition of PGE₂ release with an apparent IC₅₀ value of approximately 5 μg/mL. The ability of Sodium Salicylate to directly inhibit COX-2 activity in A549 cells is tested after a 30-min exposure period, followed by the addition of different concentrations of exogenous arachidonic acid (1, 10, and 30 μM). Sodium Salicylate causes a concentration-dependent inhibition of COX-2 activity in the absence of added arachidonic acid or in the presence of 1 or 10 μM exogenous substrate with an apparent IC₅₀ value of approximately 5 μg/mL. However, when the same experiments are performed using 30 μM arachidonic acid, Sodium Salicylate is an ineffective inhibitor of COX-2 activity, with an apparent IC₅₀ value of more than 100 μg/mL, and achieves a maximal inhibition of less than 50%.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

In C57Bl/6 DIO mice, Salicylate decreases both fasting and postprandial plasma glucose levels. Furthermore, there is a trend to reduce plasma triglyceride levels after Salicylate treatment in C57Bl/6 DIO mice (P=0.059). Salicylate significantly reduces 11β-HSD1 mRNA in omental adipose tissue in C57Bl/6 DIO mice, with a similar trend in mesenteric adipose (P=0.057). In mesenteric adipose of C57Bl/6 DIO mice, Salicylate also reduces 11β-HSD1 enzyme activity.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

ClinicalTrial

结构分类

Phenols

Ketones, Aldehydes, Acids

来源

参考文献

[1]. Mitchell JA, et al. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol. 1997 Jun;51(6):907-12. [Information]

[2]. Dongmei Bai, et al. Palmitic acid negatively regulates tumor suppressor PTEN through T366 phosphorylation and protein degradation. Cancer Lett. 2020 Oct 8;S0304-3835(20)30506-1. [Information]

[3]. Nixon M, et al. Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes. 2012 Apr;61(4):790-6. [Information]

[4]. Juhyun Oh, et al. Age-associated NF-κB signaling in myofibers alters the satellite cell niche and re-strains muscle stem cell function. Aging (Albany NY). 2016 Nov; 8(11): 2871–2884. [Information]

溶解度数据

体外研究:

H₂O : ≥ 100 mg/mL (624.61 mM)

DMSO : 100 mg/mL (624.61 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	6.2461 mL	31.2305 mL	62.4610 mL
5 mM	1.2492 mL	6.2461 mL	12.4922 mL
10 mM	0.6246 mL	3.1230 mL	6.2461 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： PBS
Solubility: 110 mg/mL (687.07 mM); Clear solution; Need ultrasonic
2.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (15.62 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (15.62 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
3.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (15.62 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (15.62 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (15.62 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (15.62 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

Sodium salicylate

相关产品

The molarity calculator equation

The dilution calculator equation